Paris, France – June 11th, 2024
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, will present data on its innovative OncoMimics
approach to cancer therapy at the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), taking place June 10-13 in Rotterdam, Netherlands. The presentation describes Enterome’s OncoMimics peptide-based immunotherapy, designed to harness the patient’s immune system to target and eliminate cancer cells.
Dr. Alice Talpin, lead researcher, commented: “The OncoMimics approach offers a promising strategy to enhance cancer immunity by overcoming the limitations of current vaccines. Our preclinical and clinical data underscore the ability of OncoMimics peptides to elicit strong, durable immune responses, which could significantly improve patient outcomes.”
Peptide-based immunotherapy offers significant potential against cancer by leveraging the body’s immune system to eliminate cancer cells, targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Enterome innovative OncoMimics therapies are based on the concept of molecular mimicry and cross-reactivity between commensal-derived synthetic peptides and tumor-associated antigens-derived peptides (TAAps) to evoke a CD8+ T cell response against tumors.
Based on this approach, Enterome has developed a pipeline of drug candidates for the treatment of cancer, including EO2463, which is demonstrating a favorable safety profile with encouraging early signs of efficacy in a Phase 2 clinical trial (EONHL1-20/SIDNEY) for indolent non-Hodgkin lymphomas, and EO2401, which has successfully completed a Phase 2 clinical trial (EOGBM1-18/ROSALIE) in patients with recurrent glioblastoma.
Highlights from the EACR 2024 poster presentation, entitled Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens:
In humanized HLA-A2 murine models, OncoMimics peptides (OMPs) trigger the expansion of cross-reactive OMP-/TAAp- specific CD8+ T cells with specific cytotoxic activity against tumor cells. Experiments conducted on HLA-A2+ healthy human peripheral blood mononuclear cells revealed a high prevalence of cross-reactive OMP-/TAAp-specific CD8+ T cells when stimulated in vitro. In addition, those cross-reactive CD8+ T cells exhibit cytolytic activity against target cells presenting homologous TAAs.
Abstract #1155 is published in an online supplement to Molecular Oncology (Volume 18, Issue S1, DOI: 10.1002/1878-0261.13683) and the Poster will be available on Enterome’s website following the session.
Poster #1155 Presentation details
Title: Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens
Presenting Author: Alice Talpin, PhD, Enterome researcher
Poster Session: Immunotherapy (odd Abstract Numbers)
Poster Board: P-285
Session Date and Time: June 12, 18:40 to 20:15 CET (poster displayed from 11:00 CET)
Contacts
| ENTEROME | MEDIA RELATIONS |
| Guillaume Bayre
Head of External Communications Tel: +33 (0)1 76 21 58 15 |
LifeSci Advisors LLC
Ashley R. Robinson (US) +1 617 430 7577 Sandya von der Weid (Europe) +41 78 680 05 38 |
Download the press release (.pdf format)
The post Enterome to Present Data on OncoMimics™ Approach to Cancer Immunotherapy at EACR 2024 appeared first on Enterome.